Clore G
You should not
AOD 9604 (an abbreviation for Anti-Obesity Drug 9604) was first developed in the 1990s in Australia in the laboratory of Professor Frank Ng, a biochemist with a long research focus on growth hormone biology
CappellariAMalagniniVFontanaPZanotelliLTonidandelLAngeliGet al
Disclosure of interest: Shubham Biyani: nothing to disclose Poster Session I - INTRACRANIAL HEMORRHAGE 02.00 - INTRACRANIAL HEMORRHAGE - 02.02 - SAH, ANEURYSMS AND VASCULAR MALFORMATIONS P150 - ESOC25-441 MINIMAL GROWTH RISK IN SMALL INCIDENTAL CAROTID OPHTHALMIC ANEURYSMS: REVISITING SURVEILLANCE INTERVALS FOR OPTIMISED MANAGEMENT Ronil Chandra 1,2 , Fergus Taylor 1 , Seana Gall 3,4 , Leon Lai 2,5 , Christopher Photopoulos 1 , Kenny Li 1 , Shreyas Honavar 1 , Lee-Anne Slater 1,6 , Thanh Phan 4,7 1 NeuroInterventional Radiology, Monash Medical Centre, Monash Health, Melbourne, Australia, 2 Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 3 Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 4 Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 5 Neurosurgery, Monash Medical Centre, Monash Health, Melbourne, Australia, 6 Department of Radiology and Radiological Sciences, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 7 Neurology, Monash Medical Centre, Monash Health, Melbourne, Australia Background and Aims: The optimal intervals for radiological surveillance of small incidental carotid ophthalmic artery (CoA) aneurysms remain uncertain, with current guidelines recommending annual or biennial imaging
5-Amino-1MQ is an unapproved research chemical that inhibits the NNMT enzyme, with neither compound holding UK marketing authorisation
